Medicare GLP-1 Bridge Eligibility 2026: Who Qualifies for $50 Wegovy, Zepbound & Foundayo?

Last updated: May 11, 2026 · Reading time: 11 minutes

Eligibility for the Medicare GLP-1 Bridge isn’t a single rule. It’s three separate pathways, each with its own BMI threshold and clinical requirements, plus a fourth pathway specifically for people who started a GLP-1 medication before the program existed. Most coverage of the program glosses over the differences between these pathways, which is a problem if you’re trying to figure out whether you actually qualify.

This guide breaks down each pathway in plain English, explains what your doctor has to document, and clarifies who doesn’t qualify under the Bridge but may still get coverage through standard Part D. If you’re new to the program, start with our complete guide to the Medicare GLP-1 Bridge.

60-Second Eligibility Check

You must be enrolled in Medicare Part D. Either a standalone Prescription Drug Plan or a Medicare Advantage plan with drug coverage. No Part D, no eligibility, even if you meet every clinical criterion below.

You must fit one of three clinical pathways, all assessed at the time you start GLP-1 therapy:

Pathway 1: BMI of 35 or higher, with no other conditions required

Pathway 2: BMI of 30-34.9, with at least one of these specific conditions: heart failure with preserved ejection fraction, uncontrolled hypertension (blood pressure above 140/90 on two antihypertensive medications), or chronic kidney disease stage 3a or higher

Pathway 3: BMI of 27-29.9, with at least one of these: pre-diabetes (per American Diabetes Association criteria), prior heart attack, prior stroke, or symptomatic peripheral artery disease

Your doctor must attest on a prior authorization request that you meet one of these pathways and that the prescription is for weight reduction combined with structured nutrition and physical activity.

If you started a GLP-1 before July 2026, eligibility is based on your BMI at the time you started therapy, not your current BMI. A prescriber attestation in the prior authorization captures this.

How the Three Eligibility Pathways Work

The Bridge isn’t open to anyone with weight to lose. CMS designed the eligibility criteria around clinical severity, which is why the BMI thresholds get lower as the comorbidities get more severe. You qualify under whichever pathway fits your situation.

Pathway 1: BMI of 35 or higher

This is the simplest pathway. If your BMI was 35 or higher when GLP-1 therapy began, you qualify. No other conditions required. According to CMS guidance summarized by Reed Smith, this pathway covers the largest share of Medicare beneficiaries with severe obesity.

To give you a sense of scale: a BMI of 35 corresponds to roughly 210 pounds at a height of 5’5″, or 235 pounds at 5’9″. Your doctor measures height and weight in the office to confirm.

Pathway 2: BMI of 30-34.9 with a qualifying severe condition

If your BMI falls between 30 and 34.9, you need at least one of three specific severe conditions to qualify:

Heart failure with preserved ejection fraction (HFpEF). Documented diagnosis with imaging and clinical history.
Uncontrolled hypertension. Specifically defined as systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg while already taking two antihypertensive medications. Hypertension that’s controlled with medication doesn’t qualify under this pathway.
Chronic kidney disease stage 3a or higher. Stage 3a means an estimated glomerular filtration rate (eGFR) between 45 and 59. Earlier-stage CKD doesn’t qualify.

The specificity matters. “Hypertension” in general isn’t the criterion. It has to be uncontrolled hypertension despite two medications. “Kidney problems” doesn’t qualify. The CKD has to be staged at 3a or higher based on lab work.

Pathway 3: BMI of 27-29.9 with a qualifying cardiovascular condition

The lowest BMI threshold requires the most established cardiovascular history. You qualify if your BMI was between 27 and 29.9 and you have at least one of:

Pre-diabetes, defined per American Diabetes Association criteria (fasting glucose 100-125 mg/dL, A1C 5.7-6.4%, or oral glucose tolerance test 140-199 mg/dL)
Prior heart attack documented in your medical record
Prior stroke documented in your medical record
Symptomatic peripheral artery disease (PAD), meaning leg pain with walking that resolves with rest, or a documented PAD diagnosis with symptoms

A few things to notice about pathway 3. Type 2 diabetes is not on this list. If you have established T2D, your GLP-1 coverage goes through standard Part D, not the Bridge. Asymptomatic peripheral artery disease, the kind found incidentally on imaging without leg symptoms, also doesn’t qualify.

[LEAD FORM PLACEHOLDER: “Check your eligibility for $50 GLP-1 coverage”]

The BMI-at-Initiation Rule (For Patients Already on a GLP-1)

This is the part that confuses the most people. Roughly 400,000 Medicare-eligible adults are already taking GLP-1s for weight loss, often paying cash prices of several hundred dollars a month. Many have lost weight and now have BMIs below the eligibility thresholds.

CMS resolved this with the BMI-at-initiation rule. Eligibility is assessed at the time GLP-1 therapy was started, not at the time of the prior authorization request.

The official CMS example: a beneficiary started GLP-1 therapy in September 2024 with a BMI of 37. By July 2026, they’ve lost weight and now have a BMI of 34. The prescriber attests in the prior authorization request that the beneficiary met the BMI of 35 or higher criterion at the time therapy began. They qualify.

This pathway is important enough that it’s worth saying clearly: if you’ve been paying out of pocket for Wegovy or Zepbound and you started below your current weight, you very likely qualify for the Bridge. Talk to your prescriber about updating your records to reflect your starting BMI, your starting weight, and your initial qualifying condition.

What your prescriber needs in your chart:

BMI at the time of GLP-1 initiation, ideally measured in clinic (not self-reported)
Documentation of any qualifying comorbidity that was present at initiation
A note showing the original prescription was for weight management

If any of those are missing, ask your prescriber to update your record before submitting the prior authorization.

Medicare Advantage vs. Original Medicare

Both work, with conditions.

If you have Original Medicare, you need a standalone Prescription Drug Plan (PDP) to be eligible for the Bridge. Original Medicare alone (Parts A and B without a PDP) doesn’t qualify. Adding a PDP requires enrolling during the Annual Enrollment Period (October 15 through December 7) or qualifying for a Special Enrollment Period.

If you have Medicare Advantage, you qualify as long as your plan includes prescription drug coverage. Most MA plans do, but a small minority (called MA-only plans) don’t. Check your plan documents for “Part D” or “prescription drug coverage.”

Special situations. According to CMS guidance, certain plan types are generally not eligible unless paired with a standalone PDP: private fee-for-service plans without drug coverage, PACE organizations, Section 1876 cost contract plans, Section 1833 health care prepayment plans, fallback plans, religious fraternal benefit plans, and employer or union group waiver plans (EGWPs).

Dual-eligible beneficiaries (people with both Medicare and Medicaid) qualify, and so do those in certain Special Needs Plans.

One important distinction: the Bridge operates outside your Part D plan entirely. Your plan doesn’t approve, deny, or administer the benefit. Even if your Part D plan has Wegovy or Zepbound on its formulary at a different price, the Bridge is what kicks in for the obesity indication. Your Part D plan’s formulary placement of GLP-1s is irrelevant for Bridge access.

Who Qualifies for GLP-1s Under Medicare But NOT Under the Bridge

This is the source of most confusion. The Bridge is specifically for the obesity indication. Other Medicare-approved uses of GLP-1s go through standard Part D, often at very different prices.

Type 2 diabetes patients. Ozempic, Mounjaro, and Rybelsus are GLP-1s approved for Type 2 diabetes. They’ve been covered under Part D for years. If you have T2D and take a GLP-1 for blood sugar control, the Bridge doesn’t apply. Your coverage continues through your Part D plan at whatever your plan’s copay structure dictates.

Cardiovascular risk reduction patients. Wegovy has a separate FDA-approved indication, beyond obesity, for reducing the risk of major cardiovascular events in adults with cardiovascular disease and either obesity or overweight. According to the FDA approval announcement, this indication has been covered by Part D since March 2024. The CV indication operates separately from the Bridge. If your Wegovy prescription is written for cardiovascular risk reduction, you pay your Part D plan’s negotiated price, not $50.

Obstructive sleep apnea patients. Zepbound is FDA-approved for moderate-to-severe OSA in adults with obesity. This indication has Part D coverage. The OSA indication is not part of the Bridge.

The peculiar consequence: a Medicare beneficiary with both Type 2 diabetes and obesity might pay their Part D plan’s copay for the same Wegovy or Zepbound prescription that a non-diabetic peer with the same BMI gets for $50 under the Bridge. The difference is which indication appears on the prior authorization.

If you have a condition that could route you through either Part D or the Bridge, talk to your prescriber about which is more financially advantageous. The answer depends on your specific Part D plan’s formulary, copay tier, and any prior authorization requirements.

What Your Doctor Needs to Document

The prior authorization request your doctor submits is what determines whether you’re approved. According to AMCP’s summary of CMS guidance, the prescriber attests to all of the following:

The drug is prescribed to reduce excess body weight and maintain weight reduction
Lifestyle modification, including structured nutrition and physical activity, is part of the treatment plan
You fall into one of the three eligibility pathways above
The BMI threshold was met at the time you started therapy (relevant if you’re already on a GLP-1)

In practical terms, your doctor’s chart should show:

A measured BMI (height and weight taken in clinic)
The relevant comorbidity diagnosis, coded with the correct ICD-10 codes
Documentation of dietary counseling and an exercise plan, which satisfies the lifestyle modification requirement

The ICD-10 codes matter for billing accuracy. Obesity is typically coded as E66.01 (morbid obesity due to excess calories) for BMIs of 40 or higher, or E66.9 (obesity, unspecified) for lower BMIs. Comorbidities get their own codes. Your doctor’s billing staff handles this, but if you’ve been told the prior auth was denied for “diagnosis code issues,” that’s the usual culprit.

For a full walkthrough of how the prior authorization process works, see the Bridge prior authorization guide (coming soon).

Frequently Asked Questions

I’m right on the edge of a BMI threshold. Will I qualify?

The BMI thresholds are bright lines. A BMI of 26.9 doesn’t qualify for pathway 3 even if every other criterion is met. A BMI of 27.0 does. Talk to your doctor about getting a measured BMI rather than relying on self-reported numbers.

Does my doctor need to be an obesity specialist?

No. Any prescriber licensed to prescribe in your state can submit the prior authorization, including primary care doctors, nurse practitioners, and physician assistants.

What if I had a heart attack 15 years ago and recovered fully?

Prior MI qualifies under pathway 3 regardless of when it occurred, provided it’s documented in your medical record. The same applies to prior stroke.

Does Type 1 diabetes count for pathway 3?

No. Pathway 3 lists pre-diabetes specifically, and the alternatives are cardiovascular conditions. Type 1 diabetes is a separate diagnosis and doesn’t qualify a beneficiary for the Bridge.

What if my BMI was higher when I started, but I never had it measured at that point?

This is a common problem for patients who started GLP-1s through telehealth. Your prescriber can attest based on clinical judgment, but having a documented starting BMI strengthens the prior authorization. If you’re in this situation, ask your prescriber what documentation they can reconstruct from your initial intake records or prior medical visits.

Can I qualify under multiple pathways?

You can fit the criteria for more than one pathway, but only one pathway needs to be attested for approval. Most patients are categorized under the pathway with the lowest BMI threshold they meet, since that requires the most documentation and provides the cleanest audit trail.

If I’m approved, do I have to re-prove eligibility every year?

CMS hasn’t published the final renewal procedures yet. Initial guidance suggests the prior authorization is good for the duration of the demonstration (through December 31, 2027), but operational details may change as the program launches. We’ll update this page when CMS publishes final renewal rules.

Sources and References

This guide is for informational purposes only and is not medical advice. Eligibility determinations are made by CMS-contracted reviewers based on documentation submitted by your prescriber. Weight Loss RX Guide is not affiliated with CMS, Medicare, Eli Lilly, or Novo Nordisk. We may receive compensation when readers connect with services through links on this site; see our affiliate disclosure for details.